表紙:治験 (臨床試験) の世界市場:成長、動向、予測
市場調査レポート
商品コード
390668

治験 (臨床試験) の世界市場:成長、動向、予測

Clinical Trials Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 120 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.10円
治験 (臨床試験) の世界市場:成長、動向、予測
出版日: 2021年07月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 120 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の治験 (臨床試験) 市場について分析し、市場の基本構造や促進・抑制要因、市場規模の動向見通し (今後6年間分)、相 (フェーズ) 別・治験計画別・地域別の詳細動向、市場競争環境 (昨今の資本取引の動きなど)、主要企業のプロファイル、今後の市場機会などについて調査しております。

第1章 イントロダクション

第2章 分析手法

第3章 エグゼクティブ・サマリー

第4章 市場のダイナミクス

  • 市場概要
  • 市場促進要因
  • 市場抑制要因
  • 業界の求心力:ポーターのファイブフォース分析

第5章 市場区分

  • 相 (フェーズ) 別
    • 第I相
    • 第II相
    • 第IIII相
    • 第IV相
  • 設計 (計画) 別
    • 治療研究
      • ランダム化比較試験
        • 二重盲検ランダム化試験
        • 一重盲検ランダム化試験
        • 非盲検ランダム化試験
      • 適応的治験
      • 非ランダム化比較試験
    • 観察研究
      • コホート研究
      • 症例対照研究
      • 横断研究 (クロスセクション研究)
      • 地域相関研究 (生態学的研究)
  • 地域別
    • 北米 (米国、カナダ、メキシコ)
    • 欧州 (ドイツ、英国、フランス、イタリア、スペインなど)
    • アジア太平洋地域 (中国、日本、インド、オーストラリア、韓国など)
    • 中東・アフリカ (湾岸協力会議 (GCC) 諸国、南アフリカなど)
    • 南米 (ブラジル、アルゼンチンなど)

第6章 競争環境

  • 企業プロファイル
    • Clinipace
    • Laboratory Corporation of America
    • Eli Lilly and Company
    • ICON PLC
    • Novo Nordisk AS
    • PAREXEL International Corporation
    • Pfizer Inc.
    • Pharmaceutical Product Development LLC
    • IQVIA
    • F. Hoffmann-La Roche Ltd
    • Sanofi
    • Wuxi AppTec

第7章 市場機会と将来動向

目次
Product Code: 49264

The clinical trials market was valued at approximately USD 38,213.3 million in 2020, and it is expected to reach USD 51,356.0 million by 2026, registering a CAGR of 5.05% during the forecast period, 2021-2026.

The major factors propelling the growth of the market include the high demand for clinical trials in emerging markets, high R&D spending of the pharmaceutical industry, an increasing prevalence of diseases, and the focus on rare diseases and multiple orphan drugs in the pipeline.

The COVID-19 pandemic has tremendously impacted the market for clinical trials, as there has been a rising focus on the development of new therapeutics or vaccines to curb or treat the disease. Also, COVID-19 has brought a slight shift in terms of the way clinical trials were performed. In the clinical trial space, usually, there has been an increased interest in virtual/decentralized trials and those have been featured on conference agendas and in magazine articles for a long time. Despite that, most companies are still opting for the same processes. However, COVID-19 has essentially forced some of the trials to move to a virtual model to keep the trials on track during this pandemic situation.

Aging is also found to be the major factor driving the burden of diseases and demand in the market studied. With the increasing burden of diseases, there has been a rising focus of the market players on developing new therapeutics for rare or genetic disorders that need specialization and focused clinical trials, which is expected to boost the market growth.

As per the World Health Organization (WHO), the burden of chronic diseases is increasing. This is expected to increase the demand for the development of new drugs and further raise the demand for clinical trials. It has been observed that almost half of the total chronic disease deaths are attributable to cardiovascular diseases, obesity, and diabetes, which are showing increasing trends. The WHO 2018 Report has also stated that chronic diseases kill 41 million people every year, which is equivalent to 71% of all deaths globally.​

The market is growing at a robust pace, owing to the advancements in healthcare and growing patented new chemical entities (NCE) indicated for various health conditions. There are also government initiatives that have motivated the small, medium, and large players to enter into drug development. Thus, there are multiple drugs in the pipeline. As a result, Novartis, GlaxoSmithKline, and Pfizer (among others) have entered this field. It has been found that the clinical trials market has taken bigger strides in the developing countries of Asia-Pacific and the Middle East, and there is still very less development in the market.

There are also stringent regulations for countries like China and India that are currently working on overcoming this issue and are successful to a considerable extent. Most emerging countries still suffer from poor regulatory infrastructure. Hence, these stringent regulations in the emerging markets are hindering the growth of the market studied.

Key Market Trends

Phase III is the Largest Segment Under Phases that is Expected to Grow During the Forecast Period

The market is expected to be dominated by Phase III, with Phase I expected to witness the fastest growth. Phase III is one of the most critical phases assessing the effectiveness of the new intervention, as well as its value in clinical practice.

Moreover, the COVID-19 pandemic has brought significant changes in the clinical trials industry and shifted the focus of many research and commercial organizations to focus on the development of new therapies and vaccines for COVID-19. For instance, in August 2020, China-based Sinopharm commenced a Phase III clinical trial of its COVID-19 vaccine candidate at the Bahrain International Exhibition and Convention Centre (BIECC).

These Phase III clinical trials are done to evaluate the comparative effect of the new medication over the previous medications available or conducted to confirm and expand on safety and effectiveness results from Phase I and II trials. These clinical trials remain a comparatively higher need for outsourcing services than Phase II and Phase I trials, owing to their greater complexity and need for a larger patient pool.

The government initiatives in emerging economies for the promotion of drug discovery and continuous technological innovations are also expected to propel the market growth.

North America Reported the Largest Growth and is Expected to Follow the Same Trend over the Forecast Period

North America has been dominating the overall market, owing to the presence of big outsourcing firms and increasing R&D in the region. This is mainly due to factors such as the increasing R&D investments and increasing demand for drug development, which are the major factors responsible for the market emergence in the United States.

With the rising COVID-19 pandemic, there is an increased burden that has shifted the focus of many organizations to the development of new therapeutics for COVID-19 with the support of the government and non-government organizations. Hence, with the rising number of COVID-19 infections, there are increasing investments in R&D activities that have led to a growing market for clinical trials.

There are also favorable government initiatives regarding clinical trials in the United States that are anticipated to boost the market growth. For instance, in March 2020, the FDA launched a Coronavirus Treatment Acceleration Program (CTAP) for possible therapies to speed up the development of treatment for the global disease caused by the coronavirus.

In the United States, pharmaceutical companies are found spending more money, time, and energy on R&D than most organizations. According to the National Institute of Health data, in the fiscal year 2017, clinical research funding by the NIH was around USD 12.7 billion, and it increased to USD 15 billion in 2019. Also, the R&D budgets of the pharmaceutical companies have increased in the past few years, owing to the rising burden of diseases, complex molecules, and therapy segments. Moreover, with the increasing of diseases, the number of clinical trials is expected to rise in the coming few years.

Competitive Landscape

The market is highly competitive in nature, and therefore, the major pharmaceutical companies are found making enormous investments in R&D, especially in the emerging nations, to gain opportunities for market growth in the major regions. The strategic partnerships among pharmaceutical companies and the CROs are expected to have a significant impact on the market's growth. In the coming years, few other players are expected to enter the market.

Also, a significant factor affecting the competitive nature is the quick adoption of advanced technology for improved healthcare. Also, to retain share and expand the product portfolio, major players are often involved in mergers and acquisitions along with new product launches.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Demand for Clinical Trials in the Emerging Markets
    • 4.2.2 High R&D Expenditure of the Pharmaceutical Industry
    • 4.2.3 Rising Prevalence of Diseases
  • 4.3 Market Restraints
    • 4.3.1 Lack of Skilled Workforce in Clinical Research
    • 4.3.2 Stringent Regulations for Patient Enrollment
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Phase
    • 5.1.1 Phase I
    • 5.1.2 Phase II
    • 5.1.3 Phase III
    • 5.1.4 Phase IV
  • 5.2 By Design
    • 5.2.1 Treatment Studies
      • 5.2.1.1 Randomized Control Trial
      • 5.2.1.2 Adaptive Clinical Trial
      • 5.2.1.3 Non-randomized Control Trial
    • 5.2.2 Observational Studies
      • 5.2.2.1 Cohort Study
      • 5.2.2.2 Case Control Study
      • 5.2.2.3 Cross Sectional Study
      • 5.2.2.4 Ecological Study
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Clinipace
    • 6.1.2 Laboratory Corporation of America
    • 6.1.3 Eli Lilly and Company
    • 6.1.4 ICON PLC
    • 6.1.5 Novo Nordisk AS
    • 6.1.6 PAREXEL International Corporation
    • 6.1.7 Pfizer Inc.
    • 6.1.8 Pharmaceutical Product Development LLC
    • 6.1.9 IQVIA
    • 6.1.10 F. Hoffmann-La Roche Ltd
    • 6.1.11 Sanofi SA
    • 6.1.12 Syneos Health
    • 6.1.13 Covance Inc.
    • 6.1.14 Theorem Clinical Research
    • 6.1.15 Charles River Laboratory

7 MARKET OPPORTUNITIES AND FUTURE TRENDS